Table 3.
Single arm prospective studies in NKTCL.
| Author | Disease status | N | Asp | CT regimen used | Treatment modality | Courses of CT | CR rate (%) | PFS (%) | OS (%) |
|---|---|---|---|---|---|---|---|---|---|
| Lee et al., 2006 (35) | Stage I/II | 16 | IMEP | CT-RT | 6 | 6CC: 69.0; ET: 81 | – | 3y: 80.4 | |
| Kim et al., 2009 (42) | Stage I/II | 30 | VIPD | CCRT-CT | Weekly DDP + 3 | ET: 80 | 3y: 85.2 | 3y: 86.3 | |
| Yamaguchi et al., 2009 (95, 96) | Stage I/II | 33 | DeVIC | CCRT | 3 | ET: 75.0 | 2y: 67.0 5y: 67.0 |
2y: 78.0 5y: 73.0 |
|
| Jiang et al., 2012 (45, 97) | Stage I/II | 26 | L-Asp | LVP | CT-RT-CT | 2 + (2–4) | 2CC: 42.3; ET: 80.8 | 2y: 80.6 5y: 64.0 |
2y: 88.5 5y: 64.0 |
| Aviles et al., 2013 (51) | Stage I/II | 202 | CMED | RT-CT | 6 | ET: 91.0 | – | 5y: 86.0 | |
| Lin et al., 2013 (49) | Stage I/II | 31 | L-Asp | CHOP | CT-RT | 6 | 4CC: 71.5; ET: 81.6 | 2y: 81.0 | 2y: 80.1 |
| Wang et al., 2013 (50) | Stage I/II | 27 | L/P-Asp | GELOX | CT-RT | 2 + 4 | 2CC: 55.6; ET: 74.1 | 2y: 86.0 | 2y: 86.0 |
| Ke et al., 2014 (52) | Stage I/II | 32 | GDP | CCRT-CT | Weekly DDP + 3 | ET: 84.4 | 3y: 84.4 | 3y: 87.5 | |
| Kim et al., 2014 (54) | Stage I/II | 44 | IMEP | CT-RT | 6 | 6CC: 27.0; ET: 67.0 | 3y: 56.0 | 3y: 66.0 | |
| Kim et al., 2014 (53) | Stage I/II | 30 | L-Asp | IMEP | CCRT-CT | weekly DDP + 2 | ET: 87.0 | 5y: 60.0 | 5y: 73.0 |
| Tsai et al., 2015 (55) | Stage I/II | 33 | DVIP | CCRT-CT | 2 DEP + 2 | ET: 42.0 | 2y: 64.0 5y: 60.0 |
2y: 73.0 5y: 66.0 |
|
| Yoon et al., 2016 (61) | Stage I/II | 28 | L-Asp | IMEP | CCRT-CT | Weekly DDP + 2 | ET: 82.1 | 3y: 74.1 | 3y: 81.5 |
| Jiang et al., 2017 (62) | Stage I/II | 66 | L-Asp | DEP | CT-CCRT-CT | 2 + 2 DDP + 2 | ET: 83.3 | 3y: 67.4 | 3y: 70.1 |
| Xu et al., 2017 (63) | Stage I/II | 40 | P-Asp | MESA | CT-RT-CT | 2 + 2 | 2CC: 71.1; ET: 89.5 | 2y: 89.1 | 2y: 92.0 |
| Qi et al., 2018 (64) | Stage I/II | 40 | GDP | RT-CT | 4 | ET: 95.0 | 2y: 84.7 5y: 79.4 |
2y: 89.9 5y: 82.1 |
|
| Zheng et al., 2018 (65) | Stage I/II | 21 | P-Asp | CHOP | RT-CT | 6 | ET: 90.5 | – | 3y: 80.5 |
| Liu et al., 2020 (66) | Stage I/II | 30 | P-Asp | DICE | RT-CT | 3 | ET: 96.7 | 5y: 86.0 | 5y: 87.0 |
| Wang et al., 2020 (67) | Stage I/II | 30 | P-Asp | P-Asp alone | CCRT-CT | 2 + 4 | ET: 100 | 2y: 90.9 | 2y: 92.8 |
| Wei et al., 2020 (68) | Stage I/II | 26 | P-Asp | GDP -ML | CT-RT-CT | 2 + 2 | ET: 76.9 | – | 2y: 88.1 |
| Zhu et al., 2020 (70) | Stage I/II | 30 | P-Asp | GDP | CCRT-CT | Weekly DDP + 3 | ET: 93.3 | 5y: 89.4 | 5y: 93.3 |
| Zhang et al., 2021 (71) | Stage I/II | 81 | L-Asp! | DICE | CT-RT | 4 | 4CC: 11.1; ET: 84.0 | 5y: 63.4 | 5y: 82.4 |
| Hu et al., 2022 (72) | Stage I/II | 64 | P-Asp | COEPL | CT-CCRT-CT | 2 + 2 (VLP) + 2 | ET: 82.0 | 3y: 78.1 | 3y: 81.2 |
| Wang et al., 2022 (73) | Stage I/II | 31 | P-Asp | GAD-M | CT-RT-CT | (2–4) + (4–2) | 2CC: 54.8; ET: 90.3 | 3y: 80.4 3y: 80.6 |
3y: 77.0 5y: 80.6 |
| Zhu et al., 2022 (74) | Stage I/II | 52 | P-Asp | GELAD | CT-RT-CT | 2 + 2 | 2CC: 46.2; ET: 92.3 | 2y: 90.4 4y: 90.4 |
2y: 94.2 4y: 94.2 |
| Lee et al., 2006 (35) | Stage III/IV | 8 | IMEP | CT alone | 13.0 | – | mOS: 2.7m 3y: 30% |
||
| Kim et al., 2009 (99) | R/R | 32 | IMEP | CT alone | 37.5 | mTTF: 3.7m | mOS: 8.2m 5y: 24.8 |
||
| Jaccard et al., 2011 (100) | R/R | 19 | L-Asp | AspMetDex | CT-RT/HSCT | 61.0 | mPFS: 12.2m | mOS: 12.2m | |
| Yamaguchi et al., 2011 (101) | Stage IV/R/R | 38 | L-Asp | SMILE | CT-HSCT (allo/auto) | 45.0 | 1y: 53 | 1y: 55 | |
| Shi et al., 2015 (158) | R/R | 16 | Chidamide | 6.0 | – | – | |||
| Zheng et al., 2018 (65) | Stage III/IV | 12 | P-Asp | CHOP | CT alone | 50.0 | – | – | |
| Wei et al., 2020 (68) | Stage III/IV | 18 | P-Asp | GDP-ML | CT-HSCT (auto) | 33.3 | 2y: 33.2 | 2y: 35.6 | |
| Kim et al., 2020 (159) | R/R | 21 | Avelumab | 24.0 | mPFS: 2.7m | – | |||
| Song et al., 2021 (114) | Stage III/IV | 27 | L-Asp | VIDL | CT-HSCT (auto) | 63.0 | mPFS: 13.2m | mOS: 27.0m | |
| Hu et al., 2022 (72) | Stage III/IV | 16 | P-Asp | COEP | CT-HSCT (auto) | 55.6 | 3y: 45.7 | 3y: 48.1 | |
| Gao et al., 2020 (160) | Asp-R | 37 | Sintilimab + chidamide | 44.4 | 1y: 66.0 | 1y: 79.1 | |||
| Huang et al., 2021 (161) | Asp-R | 32 | Daratumumab | 0 | mPFS: 53.0d | mOS: 141.0d | |||
| Tao et al., 2021 (111) | Asp-R | 28 | Sintilimab | 21.4 | – | 1y: 82.1 2y: 78.6 |
|||
| Huang et a. 2022 (98) | Asp-R | 78 | GEMSTONE-201 | 37.2 | 2y: 54.6 |
IMEP, ifosfamide, methotrexate, etoposide, and prednisone; DDP, cisplatin; VIPD, etoposide, ifosfamide, dexamethasone, and cisplatin; DeVIC, dexamethasone, etoposide, ifosfamide, and carboplatin; LVP, L-Asp, vincristine, and prednisone; GELOX, gemcitabine, L/P-Asp, and oxaliplatin; DICE, dexamethasone, ifosfamide, etoposide, and cisplatin; DEP, dexamethasone, etoposide, and cisplatin; DVIP, dexamethasone, etoposide, ifosfamide, and cisplatin; MESA, methotrexate, etoposide, dexamethasone, and PEG-Asp; CMED, cyclophosphamide, methotrexate, etoposide, and dexamethasone; SMILE, dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide; AspMetDex, L-asparaginase, methotrexate, and dexamethasone; HSCT, hematopoietic stem cell transplantation; DICE, dexamethasone, ifosfamide, cisplatin, and etoposide; GDP-ML, gemcitabine, dexamethasone, cisplatin, methotrexate, and PEG-Asp; COEPL, cyclophosphamide, vincristine, etoposide, prednisone, and P-Asp; VLP, vincristine, pegaspargase, and prednisone; GAD-M, gemcitabine, PEG-Asp, dexamethasone, and methotrexate; GELAD, gemcitabine, etoposide, PEG-Asp, dexamethasone; VIDL, etoposide, ifosfamide, dexamethasone, and L-Asp; Asp-R, asparaginase-resistant. ! L-ASP was delivered on d1-4.